

**Special Dispensing Form for Evusheld
(Tixagevimab co-packaged with Cilgavimab)**

Date		Time	
Patient Name		Patient/Iqama ID Number	
Patient Age		Patient Weight	
Requestor Name		Specialty	
Hospital Name		Region	

Is the patient suspected / confirmed with SARS-CoV-2?

- Yes No

Has the patient been exposed to an individual infected with SARS-CoV-2?

- Yes No

EVUSHELD is to be used for PRE-EXPOSURE PROPHYLAXIS in adults and pediatric (12 years of age and older weighing at least 40 kg) who have meet **one or more of the following:**

Has the patient been exempted from COVID vaccination for medical reasons?

- Yes No

Dose the patient have moderate and severe immunocompromising conditions and treated by medications that may result in an inadequate immune response to COVID-19 vaccination?

- Yes No

If yes, please choose from the following:

- Active treatment for malignancies
- Post solid-organ transplant on immunosuppressive therapy
- Advanced or untreated HIV infection
- Primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrichsyndrome)
- Taking High-dose of corticosteroids (i.e., ≥ 20 mg prednisone or equivalent per day for ≥ 2 weeks)
- Taking immunosuppressive drugs (alkylating agents, antimetabolites, Anti-Tumor Necrosis Factor (TNF), and other biologic agents)
- Hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppression therapy)
- Others (please indicate)

Administration:

- Two consecutive intramuscular doses by trained HCW in a hospital setting (e.g., admissions (non-COVID related), OPD, ER, Dialysis units).
- Prepare and observe for hypersensitivity reactions and monitor individuals after injections for at least 1 hr.
- It should be given with caution to individuals with thrombocytopenia or any coagulation disorder.